IDEXX Laboratories, Inc. Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.35 Intrinsic Value $520.01median of 6 methods · middle span $490-$617based on filings through 30 Jun 2026 Market Price $517.75Price as of 1 Oct 2026 Near fair valueIntrinsic value is 0% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $40.8B Enterprise Value $41B Shares Outstanding 79.3M diluted Moat Rating Wide Next Earnings Date2 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary IDEXX entered the second half of 2026 with strong recurring diagnostic growth, expanding diagnostic utilization, continued premium-instrument adoption, and higher margins. Q2 CAG Diagnostics recurring-revenue organic growth was 10.3%, the inVue Dx installed base exceeded 9,000 instruments, and the company raised or narrowed key FY2026 guidance ranges. The durable consumables and reference-laboratory model and new menu additions support compounding growth, while veterinary-visit pressure, competition, supplier concentration, and execution requirements remain material risks. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$470.00 Mean target$698.92 High · most bullish analyst$805.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $470.0020% CAG Diagnostics recurring-revenue organic growth falls below 9.5% and operating margin falls below 32.3% as weaker veterinary visits or diagnostic utilization, competitive pricing, supplier disruption, or slower adoption of new platforms offsets innovation and productivity benefits. Base CaseCentral scenario $698.9255% Matches the consensus meanIDEXX delivers within its FY2026 ranges, including 9.5%-10.7% CAG Diagnostics recurring-revenue organic growth and a 32.3%-32.5% operating margin. Innovation and installed-base expansion support durable growth, but veterinary-sector and macroeconomic pressure prevent a materially stronger outcome. Bull CaseUpside scenario $805.0025% CAG Diagnostics recurring-revenue organic growth remains near or above the upper end of the 9.5%-10.7% FY2026 range as premium-instrument adoption, inVue Dx utilization, reference-laboratory volumes, and new menu additions deepen customer engagement. Operating margin meets or exceeds the upper end of the 32.3%-32.5% range as recurring-revenue volume and productivity outweigh commercial and innovation investment. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |